The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Molchanova A.V.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Mikhailova E.I.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Osipkina O.V.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Association of rs1042713 and rs1042714 polymorphisms of the ADRB2 gene with response to beta-blockers in the management of portal hypertension in patients with liver cirrhosis

Authors:

Molchanova A.V., Mikhailova E.I., Osipkina O.V.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2026;15(2): 5‑12

DOI: 10.17116/dokgastro2026150215

Read: 450 times

Contact the author
Table of contents

ASSOCIATION OF RS1042713 AND RS1042714 POLYMORPHISMS OF THE ADRB2 GENE WITH RESPONSE TO BETA-BLOCKERS IN THE MANAGEMENT OF PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS
ASSOCIATION OF RS1042713 AND RS1042714 POLYMORPHISMS OF THE ADRB2 GENE WITH RESPONSE TO BETA-BLOCKERS IN THE MANAGEMENT OF PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS

To cite this article:

Molchanova AV, Mikhailova EI, Osipkina OV. Association of rs1042713 and rs1042714 polymorphisms of the ADRB2 gene with response to beta-blockers in the management of portal hypertension in patients with liver cirrhosis. Russian Journal of Evidence-Based Gastroenterology. 2026;15(2):5‑12. (In Russ.)
https://doi.org/10.17116/dokgastro2026150215

 
Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Search for info­rmative predictors of the deve­lopment and progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130
Successful repeated endo­vascular procedure for TIPS thro­mbosis. Piro­gov Russian Journal of Surgery. 2025;(11):129-133
Poly­morphism of the COMT, OPRM1, CYP2D6, CYP2B6, CYP2C9 genes and effe­ctiveness of analgesia in cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2026;(3):6-16
Case of targeted therapy in a patient with cystic fibrosis and deco­mpensated liver cirrhosis. Journal of Respiratory Medi­cine. 2026;(2):66-71
Abstract:

OBJECTIVE

To evaluate the association between polymorphic markers rs1042713 and rs1042714 of the β2-adrenergic receptor gene (ADRB2) and the response to oral propranolol in the management of portal hypertension (PH) in patients with liver cirrhosis (LC).

MATERIALS AND METHODS

A prospective cohort study included 47 unrelated patients with LC of various etiologies. Genotyping of rs1042713 and rs1042714 of the ADRB2 gene was performed using polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR–RFLP).

RESULTS

Heterozygous haplotype variants of the β2-adrenergic receptor gene were the most prevalent, observed in 51.06% of patients. Homozygous Gly16–Glu/Gln27 variants were identified in 36.17% of cases, whereas the Arg16–Gln27 haplotype was the least frequent (12.77%). Patients with the homozygous Gly16–Glu/Gln27 haplotype demonstrated the most favorable response to propranolol therapy (52.94%) compared with compound heterozygotes (20.83%) and homozygous Arg16–Gln27 carriers (0.00%). The likelihood of being a responder to propranolol therapy was more than threefold higher in carriers of the Gly16–Glu/Gln27 homozygous haplotype (p=0.01). In contrast, carriers of the Arg16–Gln27 homozygous haplotype had a 1.5-fold increased risk of non-response (p=0.0002).

CONCLUSION

Interindividual variability in propranolol efficacy in patients with LC is associated with ADRB2 gene polymorphisms. The Arg16Gly substitution in the β2-adrenergic receptor is associated with an enhanced therapeutic response to propranolol.

Keywords:

liver cirrhosis
portal hypertension
propranolol
β2-adrenergic receptor
genetic polymorphism

Authors:

Molchanova A.V.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Mikhailova E.I.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Osipkina O.V.

Educational Institution «Gomel State Medical University», Gomel, Republic of Belarus

Received:

20.05.2025

Accepted:

15.10.2025

Close metadata

References:

  1. Esophageal Varices. World Gastroenterology Organisation Global Guidelines. March 14, 2022. Accessed March 17, 2025. https://www.guidelinecentral.com/guideline/1090246
  2. Engelmann C, Jalan R. Non selective betablocker in cirrhosis: not ‘whether’ but ‘who and how’. AME Medical Journal. 2017;(2):90.  https://doi.org/10.21037/amj.2017.06.13
  3. Kong DR, Wang JG, Sun B, Wang MQ, Chen C, Yu FF, Xu JM. β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis. World Journal Gastroenterology. 2015;21(23):7191-7196. https://doi.org/10.3748/wjg.v21.i23.7191
  4. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, Noon JP. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000;36(3):371-375.  https://doi.org/10.1161/01.hyp.36.3.371
  5. Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. Beta 2-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. The Journal of Physiology. 2003;15(546):583-589.  https://doi.org/10.1113/jphysiol.2002.031138
  6. Klinicheskij protokol «Diagnostika i lechenie pacientov s zabolevaniyami organov pishchevareniya» ot 01.06.2017 №54. Accessed April 22, 2026. (In Russ.). https://minzdrav.gov.by/upload/dadvfiles/001077_838640_54gastro.pdf
  7. Bebezov BKh, Sultangaziev RA, Abdykadyrov TA. Endoscopic Prophylaxis and Treatment of Portal-Genesis Oesophageal Haemorrhage. Kreativnaya hirurgiya i onkologiya. 2022;12(2):106-111. (In Russ.). https://doi.org/10.24060/2076-3093-2022-12-2-106-111
  8. Schepke M, Raab P, Hoppe A, Schiedermaier P, Brensing KA, Sauerbruch T. Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. American Journal of Gastroenterology. 2000;95(10):2905-2909. https://doi.org/10.1111/j.1572-0241.2000.03202.x
  9. Gaiani S, Bolondi L, Fenyves D, Zironi G, Rigamonti A, Barbara L. Effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Hepatology. 1991;14(5):824-829.  https://doi.org/10.1002/hep.1840140514
  10. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. Journal of Hepatology. 2014;60(3):643-653.  https://doi.org/10.1016/j.jhep.2013.09.016
  11. Parusov AI, Sychev DA, Loranskaya ID. Pharmacotherapy personalization perspectives of portal hypertension in patients with liver cirrhosis. Eksperimental’naya i klinicheskaya gastroenterologiya. 2018;(2):142-148. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-150-2-142-148
  12. Suk KT, Kim MY, Park DH, Kim KH, Jo KW, Hong JH, Kim JW, Kim HS, Kwon SO, Baik SK. Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver. 2007;1(2):159-164.  https://doi.org/10.5009/gnl.2007.1.2.159
  13. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Ribeiro Rda C, Vieira RL, Almeida J, Nadu AP, Simões e Silva AC, Santos RA. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World Journal of Gastroenterology. 2008;14(44):6824-6830. https://doi.org/10.3748/wjg.14.6824
  14. Saigal S, Chawla Y, Dilawari JB. Assessment of effects of propranolol on portal hemodynamics in cirrhosis by duplex ultrasonography. Indian Journal of Gastroenterology. 1998;17(2):51-52. 
  15. La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. Journal of Hepatology. 2009;51(2):279-287.  https://doi.org/10.1016/j.jhep.2009.04.015
  16. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. The American Journal of Gastroenterology. 2003;98(6):1371-1376. https://doi.org/10.1111/j.1572-0241.2003.07497.x
  17. Vardeny O, Peppard PE, Finn LA, Faraco JH, Mignot E, Hla KM. β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study. Journal of the American Society of Hypertension. 2011;5(2):114-122.  https://doi.org/10.1016/j.jash.2011.01.005
  18. Lou Y, Liu J, Li Y, Liu Y, Wang Z, Liu K, Wu H, Niu Q, Gu W, Guo Y, Li Z, Wen S. Association study of the β2-adrenergic receptor gene polymorphisms and hypertension in the Northern Han Chinese. PLoS One. 2011;6(4):e18590. https://doi.org/10.1371/journal.pone.0018590
  19. Krasavtsev EL, Sennikova AV. Adrenergic agents in correction of portal hypertension in cirrhosis of the liver. Gepatologiya i gastroenterologiya. 2020;4(1):12-14. (In Russ.). https://doi.org/10.25298/2616-5546-2020-4-12-14
  20. Leonova MV. β2-adrenergic receptors genetic polymorphism, cardiovascular disorders and influence of β-blockers’ effectiveness. Consilium Medicum. 2020;22(5):92-97. (In Russ.). https://doi.org/10.26442/20751753.2020.5.200107
  21. Al-Rubaish A. β2-adrenergic receptor gene polymorphisms in normal and asthmatic individuals in the Eastern Province of Saudi Arabia. Annals of Saudi Medicine. 2011;31(6):586-590.  https://doi.org/10.4103/0256-4947.87094
  22. Fu WP, Zhao ZH, Zhong L, Sun C, Fang LZ, Liu L, Zhang JQ, Wang L, Shu JK, Wang XM, Dai LM. Relationship between polymorphisms in the 5’ leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China. Respirology. 2011;16(8):1221-1227. https://doi.org/10.1111/j.1440-1843.2011.02028.x
  23. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. The New England Journal of Medicine. 2001;345(14):1030-1035. https://doi.org/10.1056/NEJMoa010819
  24. Liggett SB. Genetic variability of the beta2 adrenergic receptor and asthma exacerbations. Thorax. 2006;61(11):925-927.  https://doi.org/10.1136/thx.2006.064006
  25. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Current Allergy and Asthma Reports. 2005;5(2):101-108.  https://doi.org/10.1007/s11882-005-0082-0
  26. Turnes J, Hernández-Guerra M, Abraldes JG, Bellot P, Oliva R, García-Pagán JC, Bosch J. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology. 2006;43(1):34-41.  https://doi.org/10.1002/hep.21000
  27. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(17):10483-10488. https://doi.org/10.1073/pnas.97.19.10483
  28. Liggett SB. Beta(2)-adrenergic receptor pharmacogenetics. American Journal of Respiratory and Critical Care Medicine. 2000;161(3 Pt 2):S197-S201. https://doi.org/10.1164/ajrccm.161.supplement_2.a1q4-10
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.